Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

Provider resource · last updated October 20, 2026

Peptide regulatory landscape.

The peptide regulatory landscape shifted significantly in early 2026. Following HHS Secretary Robert F. Kennedy Jr.'s February 27, 2026 announcement, approximately 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list would be returned to Category 1. As of October 2026 FDA has not finalized that change, so whether licensed 503A pharmacies may compound these peptides is still unsettled and availability varies. The FDA continues to refine its approach to compounded peptides under the FD&C Act, and state boards of pharmacy and medicine continue to issue their own guidance. Providers must stay current on federal rules, the 503A/503B framework, and state-specific restrictions to maintain compliant practices.

Active alerts
14
Peptides tracked
12
State notes
5
Last updated
October 20, 2026

01

Active regulatory alerts

Newest first. Live items come from our daily regulatory news check; each links to its source.

  1. October 20, 2026

    critical

    STAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loophole

    A bipartisan coalition of lawmakers has formally urged the FDA to address a regulatory loophole currently being exploited to import unauthorized compounded versions of retatrutide, Eli Lilly's investigational obesity peptide. The request centers on closing the pathway that allows knockoff formulations of the unapproved drug to enter the United States market outside of standard FDA oversight. The development signals growing congressional attention to peptide importation enforcement and the integrity of the drug approval process.

    Source: STAT NewsRead more

  2. October 16, 2026

    critical

    CHMP endorses Eli Lilly's GLP-1 pill and three other new drugs

    The European Medicines Agency's Committee for Human Medicinal Products has endorsed orforglipron, Eli Lilly's oral GLP-1 receptor agonist, representing a major milestone in the race to bring non-injectable weight management therapies to market. The approval recommendation positions Lilly to compete directly with Novo Nordisk's oral semaglutide offering in the European market. This development signals continued momentum in the oral small-molecule GLP-1 space and may have implications for global prescribing patterns and compounding demand.

    Source: Endpoints NewsRead more

  3. October 16, 2026

    critical

    FDA considers interim access for compounded peptides; Enspryng's label expansion

    The FDA and HHS have submitted an interim access policy for compounding using certain peptides to the White House Office of Information and Regulatory Affairs for review, marking a significant potential shift in how compounded peptides are regulated and accessed. The proposed policy could open pathways for compounding pharmacies to legally produce specific peptide compounds that have faced regulatory uncertainty in recent years. Providers and compounding pharmacies are closely watching this development as it moves through the federal review process.

    Source: Endpoints NewsRead more

  4. October 15, 2026

    critical

    Trump Administration Advances Plan for Peptides Favored by RFK Jr.

    U.S. health officials are moving forward with a framework to allow specialty pharmacies to produce certain peptide compounds, marking a notable shift in the regulatory landscape surrounding these widely used injectable therapies. The initiative has gained public visibility in part due to Health Secretary Robert F. Kennedy Jr.'s vocal support for peptide-based treatments, which have seen surging demand among wellness and longevity-focused patients. The policy development is poised to reshape compounding pharmacy access to peptides and may establish clearer guidelines for an industry that has long operated without formal federal oversight.

    Source: MedPage TodayRead more

  5. October 15, 2026

    critical

    Trump administration advances plan for peptide drugs favored by RFK Jr.

    U.S. health officials are actively advancing a regulatory framework that would permit specialty pharmacies to compound and dispense certain peptide therapies, a category of injectable substances that has grown substantially in popularity but has operated in a largely unregulated space. The plan, which has drawn attention due to Health Secretary Robert F. Kennedy Jr.'s public support for peptide therapies, represents a significant policy shift in how compounding pharmacies may access and produce these compounds. The outcome of this regulatory effort is expected to have broad implications for providers, patients, and the compounding pharmacy industry.

    Source: STAT NewsRead more

  6. October 13, 2026

    critical

    Bootleg Retatrutide Deaths? PMOS and Dementia; Weight-Loss Drug to Be Discontinued

    Two deaths linked to counterfeit versions of retatrutide, an investigational triple receptor agonist weight-loss compound, have been reported to the FDA, raising urgent safety concerns around illicit peptide manufacturing. The reports underscore the public health risks associated with unregulated compounding and black-market distribution of unapproved peptide therapies. Ongoing litigation alleging severe adverse events from GLP-1 receptor agonists adds further regulatory and clinical scrutiny to this drug class.

    Source: MedPage TodayRead more

  7. October 7, 2026

    critical

    WHO advises against obesity drugs for younger children

    The World Health Organization has issued guidance recommending that GLP-1 receptor agonists not be prescribed to children under age 10 for obesity treatment, while advising that adolescents ages 10 to 19 should only receive these therapies after supervised lifestyle interventions have failed. The guidance introduces a significant new layer of global regulatory framing around pediatric use of GLP-1 drugs. This development is likely to influence prescribing standards and regulatory postures in markets worldwide.

    Source: Endpoints NewsRead more

  8. September 23, 2026

    critical

    FDA Warns Pharmacy About Illegal GLP-1 Compounding

    The FDA issued a formal warning letter to Empower Pharmacy citing illegal copycat manufacturing of compounded GLP-1 weight-loss and diabetes drugs alongside insanitary facility conditions. The enforcement action underscores the agency's continued scrutiny of compounding pharmacies producing semaglutide and tirzepatide formulations outside approved regulatory frameworks. This development carries significant compliance implications for providers and pharmacies operating in the compounded GLP-1 space.

    Source: MedPage TodayRead more

  9. September 22, 2026

    critical

    Compounder Empower receives FDA warning letter over GLP-1s

    The FDA has issued a warning letter to Empower Pharmacy, a Houston-based compounding facility, regarding its compounded GLP-1 weight loss treatments, marking the third such warning the company has received in under two years. The action signals intensifying federal scrutiny of compounding pharmacies operating in the GLP-1 space following the resolution of shortage designations for semaglutide and tirzepatide. Providers and compounders should treat this enforcement action as a material compliance development with direct implications for compounded GLP-1 dispensing practices.

    Source: Endpoints NewsRead more

  10. September 15, 2026

    critical

    Centric Compounding recalls three injectables over contamination

    Centric Compounding, a Houston-based pharmacy, has initiated a nationwide recall of three injectable drug lots due to contamination concerns involving an active pharmaceutical ingredient. The recall includes lots of the compounded peptide injectable Glutathione, raising patient safety concerns across the compounding sector. This action underscores ongoing regulatory scrutiny of sterile injectable compounding practices and quality control standards.

    Source: Endpoints NewsRead more

  11. 2026-02-27

    critical

    HHS Announces Plan to Return 14 Peptides to Category 1

    On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list will be moved back to Category 1. Affected peptides include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, Selank, and Semax. The announcement is not itself a final FDA action: as of October 2026 FDA has not finalized the change, so 503A compounding of these peptides remains unsettled. Reclassification does NOT mean the peptides are FDA-approved drugs, the 503A framework, documentation, and medical-necessity requirements still apply.

    Source: HHS / FDA

  12. 2026-04-01

    critical

    FDA Clarifies Compounded GLP-1 Policy and 'Essentially a Copy' Standard

    On April 1, 2026, the FDA issued clarifying guidance reminding 503A pharmacies and 503B outsourcing facilities that compounded drugs qualify for the FD&C Act statutory exemptions only when applicable conditions are satisfied, with specific focus on the 'essentially a copy' standard. Because the tirzepatide shortage was resolved in December 2024 and the semaglutide shortage in February 2025, compounders preparing GLP-1 analogues must document clinical-difference justification for each patient and should review their 'essentially a copy' analysis.

    Source: FDA.gov

  13. 2026-03-20

    high

    GLP-1 Shortages Resolved: Wind-Down Period Enforcement

    The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. Compounding under shortage provisions has ended, and phased enforcement grace periods have expired. 503A pharmacies may continue patient-specific compounding only where a documented clinical difference justifies it (not as an essential copy of the commercial product). Providers should verify each prescription meets the 'essentially a copy' standard.

    Source: FDA Drug Shortage Database

  14. 2026-02-28

    medium

    DEA Scheduling Considerations for Peptide Practices

    While most therapeutic peptides are not scheduled substances, providers should be aware that certain peptide hormones (e.g., synthetic growth hormone analogues) may trigger DEA scrutiny depending on intended use. Maintain thorough documentation of medical necessity for all peptide prescriptions.

    Source: DEA Diversion Control

02

Peptide status tracker

FDA and compounding status for commonly prescribed peptides. The verdict matches each compound's profile; open a row for the detail.

  • BPC-157Awaiting FDA decision · medium risk
    FDA status
    Not FDA-Approved; Category 1 announced Feb 2026, not finalized by FDA
    Compounding eligibility
    Unsettled: HHS announced a return to Category 1 in February 2026; FDA has not finalized it
    Provider notes
    HHS announced a return to Category 1 on February 27, 2026. On July 23-24, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC-157 to the 503A bulks list; FDA staff had recommended against. The vote is advisory and FDA has not finalized BPC-157's status, so pharmacy availability varies. Still not FDA-approved as a finished drug.

    Last reviewed 2026-10-07

  • SemaglutideFDA-approved · high risk
    FDA status
    FDA-Approved (Ozempic, Wegovy, Rybelsus)
    Compounding eligibility
    Shortage resolved February 2025, compounding only where a documented clinical difference justifies it (not as an essential copy)
    Provider notes
    Shortage resolved; enforcement grace period has ended. Compounding must satisfy the 'essentially a copy' standard on a per-patient basis. April 1, 2026 FDA clarification reaffirmed this position.

    Last reviewed 2026-04-08

  • TirzepatideFDA-approved · high risk
    FDA status
    FDA-Approved (Mounjaro, Zepbound)
    Compounding eligibility
    Shortage resolved December 2024, compounding only where a documented clinical difference justifies it (not as an essential copy)
    Provider notes
    Shortage resolved; enforcement grace period has ended. Eli Lilly continues to pursue enforcement against mass-compounding. Per-patient clinical justification required.

    Last reviewed 2026-04-08

  • PT-141 (Bremelanotide)FDA-approved · medium risk
    FDA status
    FDA-Approved (Vyleesi)
    Compounding eligibility
    503A compounding may be restricted as a copy of commercially available drug
    Provider notes
    Commercially available as Vyleesi. Compounding as an essentially copy may violate 503A provisions.

    Last reviewed 2026-02-15

  • CJC-1295Awaiting FDA decision · medium risk
    FDA status
    Not FDA-Approved; Category 1 announced Feb 2026, not finalized by FDA
    Compounding eligibility
    Unsettled: HHS announced a return to Category 1 in February 2026; FDA has not finalized it
    Provider notes
    Growth hormone releasing peptide. Named in the February 27, 2026 HHS announcement of a return to Category 1, which FDA has not finalized.

    Last reviewed 2026-04-08

  • IpamorelinAwaiting FDA decision · medium risk
    FDA status
    Not FDA-Approved; Category 1 announced Feb 2026, not finalized by FDA
    Compounding eligibility
    Unsettled: HHS announced a return to Category 1 in February 2026; FDA has not finalized it
    Provider notes
    Commonly paired with CJC-1295. Named in the February 27, 2026 HHS announcement of a return to Category 1, which FDA has not finalized.

    Last reviewed 2026-04-08

  • Thymosin Alpha-1Awaiting FDA decision · medium risk
    FDA status
    Not FDA-Approved in US (approved internationally); Category 1 announced Feb 2026, not finalized by FDA
    Compounding eligibility
    Unsettled: HHS announced a return to Category 1 in February 2026; FDA has not finalized it
    Provider notes
    Used internationally under brand name Zadaxin. Named in the February 27, 2026 HHS announcement of a return to Category 1, which FDA has not finalized.

    Last reviewed 2026-04-08

  • Thymosin Beta-4 (TB-500)Awaiting FDA decision · medium risk
    FDA status
    Not FDA-Approved; Category 1 announced Feb 2026, not finalized by FDA
    Compounding eligibility
    Unsettled: HHS announced a return to Category 1 in February 2026; FDA has not finalized it
    Provider notes
    Named in the February 27, 2026 HHS announcement of a return to Category 1, which FDA has not finalized. Providers should maintain robust safety monitoring and informed consent given limited clinical data.

    Last reviewed 2026-04-08

  • AOD-9604Awaiting FDA decision · medium risk
    FDA status
    Not FDA-Approved; Category 1 announced Feb 2026, not finalized by FDA
    Compounding eligibility
    Unsettled: HHS announced a return to Category 1 in February 2026; FDA has not finalized it
    Provider notes
    Anti-obesity peptide fragment. Named in the February 27, 2026 HHS announcement of a return to Category 1, which FDA has not finalized. Clinical evidence remains limited; document medical necessity carefully.

    Last reviewed 2026-04-08

  • SelankAwaiting FDA decision · medium risk
    FDA status
    Not FDA-Approved; Category 1 announced Feb 2026, not finalized by FDA
    Compounding eligibility
    Unsettled: HHS announced a return to Category 1 in February 2026; FDA has not finalized it
    Provider notes
    Neuropeptide studied for anxiolytic and cognitive effects. Named in the February 27, 2026 HHS announcement of a return to Category 1, which FDA has not finalized.

    Last reviewed 2026-04-08

  • SemaxAwaiting FDA decision · medium risk
    FDA status
    Not FDA-Approved; Category 1 announced Feb 2026, not finalized by FDA
    Compounding eligibility
    Unsettled: HHS announced a return to Category 1 in February 2026; FDA has not finalized it
    Provider notes
    Neuropeptide studied for cognitive function and neuroprotection. Named in the February 27, 2026 HHS announcement of a return to Category 1, which FDA has not finalized.

    Last reviewed 2026-04-08

  • GHK-CuNo lawful US pathway · low risk
    FDA status
    Not FDA-Approved as drug
    Compounding eligibility
    Topical formulations may fall under cosmetic vs. drug classification
    Provider notes
    Regulatory classification depends on intended use and claims made. Topical use may be classified as cosmetic rather than drug.

    Last reviewed 2026-02-10

03

Federal Regulatory Framework

  1. 01FDA Oversight of Peptides

    Peptides used therapeutically fall under FDA jurisdiction as drugs. Commercially manufactured peptide drugs require full NDA/BLA approval. Compounded peptides are regulated under Section 503A (patient-specific prescriptions by licensed pharmacies) and Section 503B (outsourcing facilities that can compound without patient-specific prescriptions but must comply with cGMP requirements).

  2. 02503A Compounding Requirements

    Under Section 503A, a licensed pharmacist or clinician may compound a drug product for an individual patient based on a valid prescription. The peptide must appear on the FDA's approved bulk drug substance list or be a component of an FDA-approved drug. The pharmacy cannot advertise or promote specific compounded drugs, and the compounded product cannot be essentially a copy of a commercially available drug.

    • Requires valid patient-specific prescription
    • Bulk substance must be on FDA list or USP-NF monograph
    • Cannot be a copy of a commercially available drug
    • Cannot advertise specific compounded products
    • Must comply with USP <795> and <797> standards
    • State board of pharmacy oversight applies
  3. 03503B Outsourcing Facilities

    Section 503B outsourcing facilities are registered with FDA and can compound without individual patient prescriptions. They must comply with current Good Manufacturing Practice (cGMP) requirements, report adverse events, and submit to FDA inspections. Products must be compounded from bulk substances that are components of FDA-approved drugs or on the 503B bulks list.

    • Must register with FDA as outsourcing facility
    • Subject to cGMP requirements and FDA inspection
    • Can distribute without patient-specific prescriptions
    • Must report adverse events to FDA
    • Must provide product labels with standard drug labeling info
    • Subject to FDA recall authority
  4. 04Bulk Drug Substance Nominations

    The FDA maintains a list of bulk drug substances that can be used in compounding under 503A and 503B. Substances not on this list or not components of FDA-approved drugs may not be compounded. The FDA periodically reviews nominations for additions or removals. Providers should track the status of peptides they prescribe on the FDA's bulk drug substance evaluation page.

04

Provider compliance checklist

Use this checklist to verify your practice meets current regulatory requirements. This is for guidance only and does not constitute legal advice.

01

Sourcing & Supply Chain

02

Prescribing & Documentation

03

State Compliance

04

Marketing & Advertising

05

State regulatory notes

Peptide regulation varies by state. These notes highlight key considerations for select states. Always verify with your state board.

Florida

Florida Board of Medicine has been active in reviewing peptide therapy practices. Telehealth-friendly state with clear compounding pharmacy regulations.

Updated 2026-03-01

Texas

Texas Medical Board requires thorough documentation for peptide prescriptions. State has specific rules about clinician dispensing of compounded drugs.

Updated 2026-03-01

California

California Board of Pharmacy maintains strict oversight of compounding pharmacies. State has additional requirements beyond federal 503A/503B framework.

Updated 2026-02-15

New York

New York has stringent compounding regulations. Providers should be aware of state-specific sterile compounding requirements that may exceed USP standards.

Updated 2026-02-15

Arizona

Arizona has a relatively permissive regulatory environment for compounded medications. Naturopathic clinicians have prescriptive authority for peptides.

Updated 2026-02-01

06

Regulatory timeline

  1. 2013Drug Quality and Security Act (DQSA) signed into law, creating the 503B outsourcing facility category and modernizing the 503A framework
  2. 2019FDA begins systematic review of bulk drug substances nominated for use in compounding under 503B
  3. 2023FDA issues warning letters to multiple compounding pharmacies over peptide product quality concerns
  4. 2024FDA intensifies scrutiny of compounded GLP-1 agonists (semaglutide, tirzepatide) amid drug shortage provisions
  5. Dec 2024FDA declares the tirzepatide shortage resolved, beginning a phased wind-down for compounders
  6. Feb 2025FDA declares the semaglutide shortage resolved; enforcement grace period begins for 503A and 503B compounders
  7. 2025Multiple states update guidance on peptide therapy prescribing practices and telehealth peptide consultations
  8. Feb 27, 2026HHS Secretary Robert F. Kennedy Jr. announces that approximately 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list will be returned to Category 1 (not finalized by FDA as of October 2026), naming peptides including BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, Selank, and Semax
  9. Apr 1, 2026FDA issues clarification for 503A pharmacies and 503B outsourcing facilities reinforcing the 'essentially a copy' standard for compounded GLP-1 products following shortage resolution

Community

Join our community

Connect with patients, health enthusiasts, and providers discussing peptide therapy, regulatory updates, and the latest research.

Join the community

Legal disclaimer

This page is for educational and informational purposes only and does not constitute legal or regulatory advice. Regulatory requirements change frequently. Providers should consult with qualified legal counsel and verify current regulations with the FDA, their state board of medicine, and state board of pharmacy before making compliance decisions.